Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
Design Therapeutics (DSGN) Stock Price & Analysis
54 Followers
DSGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.90 - $26.30
Previous Close$5.63
Volume137.74K
Average Volume (3M)378.25K
Market Cap
$335.11M
Enterprise Value$22.60M
Total Cash (Recent Filing)$315.39M
Total Debt (Recent Filing)$2.88M
Price to Earnings (P/E)-4.5
Beta1.66
Next Earnings
Nov 07, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding55,945,551
10 Day Avg. Volume177,768
30 Day Avg. Volume378,247
Standard Deviation0.19
R-Squared0.12
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$26.50Price Target Upside370.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Design Therapeutics News
Pre-EarningsIs DSGN a Buy, Before Earnings?
Stock Analysis & IdeasDown More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $4.90 and its highest was $26.30 in the past 12 months.
What is Design Therapeutics’s market cap?
Currently, no data Available
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 159 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on May 09, 2023. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.008.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 55,945,553 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went down -11.656%.
Which hedge fund is a major shareholder of Design Therapeutics?
Among the largest hedge funds holding Design Therapeutics’s share is RA Capital Management. It holds Design Therapeutics’s shares valued at 17M.
---
Design Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.50 (370.69% Upside)
$26.50 (370.69% Upside)
Blogger Sentiment
Bearish
DSGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 65.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.88%
12-Months-Change
Fundamentals
Return on Equity
-20.30%
Trailing 12-Months
Asset Growth
-14.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Design Therapeutics
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
---
Top 5 ETFs holding DSGN
Schwab U.S. Broad Market ETF
$107.57K
iShares Russell 3000 ETF
$53.97K
Invesco Nasdaq Biotechnology ETF
$6.67K
Up to five ETFs with an Outperform Smart Score that hold DSGN. The ETFs are listed according to market value of DSGN within the ETF
---
---